To include your compound in the COVID-19 Resource Center, submit it here.

RG-101: FDA hold

FDA placed a full clinical hold on RG-101 after Regulus reported a second severe adverse event of jaundice in an RG-101-treated patient. An HCV-infected patient

Read the full 256 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE